EIDD-1931 NHC 60 mg Tablets – Unapproved Product

EIDD-1931, also called NHC or N4-hydroxycytidine, is a nucleoside analogue investigated in antiviral research. This product lists 60 mg tablets with 30 tablets, carrying the product’s existing unapproved-product notice.

Ingredient research context

Published research investigates NHC activity through changes introduced during viral RNA replication. Much of that work concerns defined laboratory or experimental formulations. Research about an ingredient does not establish the quality, clinical suitability or approval of an unspecified marketed tablet.

NHC tablets and molnupiravir capsules differ

Molnupiravir is a related prodrug converted to NHC, but the two are different chemical/formulation presentations. The listed 60 mg NHC tablet is not an interchangeable 200 mg molnupiravir capsule or a laboratory reagent pack.

Strength and count do not define a treatment

60 mg identifies the listed amount per tablet and 30 is the tablet count. They do not supply an administration schedule, a course length or a diagnosis. A veterinary enquiry requires the complete product identity and independent professional assessment.

Keep the status and formulation explicit

Match the named product, tablet form, strength and full label. Clinical instructions for a different antiviral or research material should not be transferred to this product because the ingredient names are related.